Punnee Pitisuttithum1, Sorachai Nitayaphan2, Suwat Chariyalertsak3, Jaranit Kaewkungwal1, Peter Dawson4, Jittima Dhitavat1, Benjaluck Phonrat1, Siriwat Akapirat2, Nicos Karasavvas5, Lindsay Wieczorek6, Victoria Polonis7, Michael A Eller6, Poonam Pegu6, Dohoon Kim6, Alexandra Schuetz8, Surat Jongrakthaitae2, Yingjun Zhou4, Faruk Sinangil9, Sanjay Phogat10, Carlos A Diazgranados11, James Tartaglia11, Elizabeth Heger12, Kirsten Smith2, Nelson L Michael7, Jean-Louis Excler13, Merlin L Robb6, Jerome H Kim14, Robert J O'Connell15, Sandhya Vasan16. 1. Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. 2. Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand. 3. Research Institute for Health Sciences and Faculty of Public Health, Chiang Mai University, Chiang Mai, Thailand. 4. The Emmes Corporation, Rockville, MD, USA. 5. Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA. 6. US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA; Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA. 7. US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA. 8. Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA; Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA. 9. Global Solutions for Infectious Diseases, South San Francisco, CA, USA. 10. Sanofi Pasteur, Swiftwater, PA, USA; GlaxoSmithKline, Siena, Italy. 11. Sanofi Pasteur, Swiftwater, PA, USA. 12. US Army Medical Materiel Development Activity, Fort Detrick, MD, USA. 13. US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA; Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA; International Vaccine Institute, Seoul, South Korea. 14. US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA; International Vaccine Institute, Seoul, South Korea. 15. Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA. 16. Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA; Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA. Electronic address: svasan@hivresearch.org.
Abstract
BACKGROUND: The RV144 phase 3 vaccine trial in Thailand demonstrated that ALVAC-HIV (vCP1521) and AIDSVAX B/E administration over 6 months resulted in a 31% efficacy in preventing HIV acquisition. In this trial, we assessed the immunological effect of an additional vaccine boost to the RV144 regimen at varying intervals between the priming vaccine series and the boost. METHODS:RV306 is a double-blind, placebo-controlled, randomised clinical trial done at three clinical sites in Thailand. Eligible volunteers were HIV-uninfected individuals aged 20-40 years who were at low risk for HIV infection and in good health. A randomisation schedule was centrally generated with fixed sized strata for Research Institute for Health Sciences Chiang Mai and combined Bangkok clinics. Participants were randomly assigned to one of five groups and then further randomly assigned to either vaccine or placebo. All participants received the primary RV144 vaccine series at months 0, 1, 3, and 6. Group 1 received no additional boost, group 2 received additional AIDSVAX B/E and ALVAC-HIV (vCP1521) or placebo at month 12, group 3 received AIDSVAX B/E alone or placebo at month 12, group 4a received AIDSVAX B/E and ALVAC-HIV or placebo at month 15, and group 4b received AIDSVAX B/E and ALVAC-HIV or placebo at month 18. Primary outcomes were safety and tolerability of these vaccination regimens and cellular and humoral immune responses compared between the RV144 series alone and regimens with late boosts at different timepoints. Safety and tolerability outcomes were assessed by evaluating local and systemic reactogenicity and adverse events in all participants. This trial is registered at ClinicalTrials.gov (NCT01931358); clinical follow-up is now complete. FINDINGS:Between Oct 28, 2013, and April 29, 2014, 367 participants were enrolled, of whom 27 were assignedactive vaccination in group 1, 102 in group 2, 101 in group 3, 52 in group 4a, 51 in group 4b, and 34 combined placebo across all the groups. No vaccine-related serious adverse events were recorded. Occurrence and severity of local and systemic reactogenicity were similar across active groups. Groups with late boosts (groups 2, 3, 4a, and 4b) had increased peak plasma IgG-binding antibody levels against gp70 V1V2 relative to group 1 vaccine recipients with no late boost (gp70 V1V2 92TH023 adjusted p<0·02 for each; gp70 V1V2 CaseA2 adjusted p<0·0001 for each). Boosting at month 12 (groups 2 and 3) did not increase gp120 responses compared with the peak responses after the RV144 priming regimen at month 6; however, boosting at month 15 (group 4a) improved responses to gp120 A244gD- D11 (p=0·0003), and boosting at month 18 (group 4b) improved responses to both gp120 A244gD- D11 (p<0·0001) and gp120 MNgD- D11 (p=0·0016). Plasma IgG responses were significantly lower among vaccine recipients boosted at month 12 (pooled groups 2 + 3) than at month 15 (group 4a; adjusted p<0·0001 for each, except for gp70 V1V2 CaseA2, p=0·0142) and at month 18 (group 4b; all adjusted p<0·001). Boosting at month 18 versus month 15 resulted in a significantly higher plasma IgG response to gp120 antigens (all adjusted p<0·01) but not gp70 V1V2 antigens. CD4 functionality and polyfunctionality scores after stimulation with HIV-1 Env peptides (92TH023) increased with delayed boosting. Groups with late boosts had increased functionality and polyfunctionality scores relative to vaccine recipients with no late boost (all adjusted p<0·05, except for the polyfunctionality score in group 1 vs group 4b, p<0·01). INTERPRETATION: Taken together, these results suggest that additional boosting of the RV144 regimen with longer intervals between the primary vaccination series and late boost improved immune responses and might improve the efficacy of preventing HIV acquisition. FUNDING: US National Institute of Allergy and Infectious Diseases and US Department of the Army.
RCT Entities:
BACKGROUND: The RV144 phase 3 vaccine trial in Thailand demonstrated that ALVAC-HIV (vCP1521) and AIDSVAX B/E administration over 6 months resulted in a 31% efficacy in preventing HIV acquisition. In this trial, we assessed the immunological effect of an additional vaccine boost to the RV144 regimen at varying intervals between the priming vaccine series and the boost. METHODS:RV306 is a double-blind, placebo-controlled, randomised clinical trial done at three clinical sites in Thailand. Eligible volunteers were HIV-uninfected individuals aged 20-40 years who were at low risk for HIV infection and in good health. A randomisation schedule was centrally generated with fixed sized strata for Research Institute for Health Sciences Chiang Mai and combined Bangkok clinics. Participants were randomly assigned to one of five groups and then further randomly assigned to either vaccine or placebo. All participants received the primary RV144 vaccine series at months 0, 1, 3, and 6. Group 1 received no additional boost, group 2 received additional AIDSVAX B/E and ALVAC-HIV (vCP1521) or placebo at month 12, group 3 received AIDSVAX B/E alone or placebo at month 12, group 4a received AIDSVAX B/E and ALVAC-HIV or placebo at month 15, and group 4b received AIDSVAX B/E and ALVAC-HIV or placebo at month 18. Primary outcomes were safety and tolerability of these vaccination regimens and cellular and humoral immune responses compared between the RV144 series alone and regimens with late boosts at different timepoints. Safety and tolerability outcomes were assessed by evaluating local and systemic reactogenicity and adverse events in all participants. This trial is registered at ClinicalTrials.gov (NCT01931358); clinical follow-up is now complete. FINDINGS: Between Oct 28, 2013, and April 29, 2014, 367 participants were enrolled, of whom 27 were assigned active vaccination in group 1, 102 in group 2, 101 in group 3, 52 in group 4a, 51 in group 4b, and 34 combined placebo across all the groups. No vaccine-related serious adverse events were recorded. Occurrence and severity of local and systemic reactogenicity were similar across active groups. Groups with late boosts (groups 2, 3, 4a, and 4b) had increased peak plasma IgG-binding antibody levels against gp70 V1V2 relative to group 1 vaccine recipients with no late boost (gp70 V1V2 92TH023 adjusted p<0·02 for each; gp70 V1V2 CaseA2 adjusted p<0·0001 for each). Boosting at month 12 (groups 2 and 3) did not increase gp120 responses compared with the peak responses after the RV144 priming regimen at month 6; however, boosting at month 15 (group 4a) improved responses to gp120 A244gD- D11 (p=0·0003), and boosting at month 18 (group 4b) improved responses to both gp120 A244gD- D11 (p<0·0001) and gp120 MNgD- D11 (p=0·0016). Plasma IgG responses were significantly lower among vaccine recipients boosted at month 12 (pooled groups 2 + 3) than at month 15 (group 4a; adjusted p<0·0001 for each, except for gp70 V1V2 CaseA2, p=0·0142) and at month 18 (group 4b; all adjusted p<0·001). Boosting at month 18 versus month 15 resulted in a significantly higher plasma IgG response to gp120 antigens (all adjusted p<0·01) but not gp70 V1V2 antigens. CD4 functionality and polyfunctionality scores after stimulation with HIV-1Env peptides (92TH023) increased with delayed boosting. Groups with late boosts had increased functionality and polyfunctionality scores relative to vaccine recipients with no late boost (all adjusted p<0·05, except for the polyfunctionality score in group 1 vs group 4b, p<0·01). INTERPRETATION: Taken together, these results suggest that additional boosting of the RV144 regimen with longer intervals between the primary vaccination series and late boost improved immune responses and might improve the efficacy of preventing HIV acquisition. FUNDING: US National Institute of Allergy and Infectious Diseases and US Department of the Army.
Authors: Allan deCamp; Peter Hraber; Robert T Bailer; Michael S Seaman; Christina Ochsenbauer; John Kappes; Raphael Gottardo; Paul Edlefsen; Steve Self; Haili Tang; Kelli Greene; Hongmei Gao; Xiaoju Daniell; Marcella Sarzotti-Kelsoe; Miroslaw K Gorny; Susan Zolla-Pazner; Celia C LaBranche; John R Mascola; Bette T Korber; David C Montefiori Journal: J Virol Date: 2013-12-18 Impact factor: 5.103
Authors: Mattia Bonsignori; Kwan-Ki Hwang; Xi Chen; Chun-Yen Tsao; Lynn Morris; Elin Gray; Dawn J Marshall; John A Crump; Saidi H Kapiga; Noel E Sam; Faruk Sinangil; Marie Pancera; Yang Yongping; Baoshan Zhang; Jiang Zhu; Peter D Kwong; Sijy O'Dell; John R Mascola; Lan Wu; Gary J Nabel; Sanjay Phogat; Michael S Seaman; John F Whitesides; M Anthony Moody; Garnett Kelsoe; Xinzhen Yang; Joseph Sodroski; George M Shaw; David C Montefiori; Thomas B Kepler; Georgia D Tomaras; S Munir Alam; Hua-Xin Liao; Barton F Haynes Journal: J Virol Date: 2011-07-27 Impact factor: 5.103
Authors: Barton F Haynes; Peter B Gilbert; M Juliana McElrath; Susan Zolla-Pazner; Georgia D Tomaras; S Munir Alam; David T Evans; David C Montefiori; Chitraporn Karnasuta; Ruengpueng Sutthent; Hua-Xin Liao; Anthony L DeVico; George K Lewis; Constance Williams; Abraham Pinter; Youyi Fong; Holly Janes; Allan DeCamp; Yunda Huang; Mangala Rao; Erik Billings; Nicos Karasavvas; Merlin L Robb; Viseth Ngauy; Mark S de Souza; Robert Paris; Guido Ferrari; Robert T Bailer; Kelly A Soderberg; Charla Andrews; Phillip W Berman; Nicole Frahm; Stephen C De Rosa; Michael D Alpert; Nicole L Yates; Xiaoying Shen; Richard A Koup; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Nelson L Michael; Jerome H Kim Journal: N Engl J Med Date: 2012-04-05 Impact factor: 91.245
Authors: E S Rosenberg; J M Billingsley; A M Caliendo; S L Boswell; P E Sax; S A Kalams; B D Walker Journal: Science Date: 1997-11-21 Impact factor: 47.728
Authors: Peter Gilbert; Maggie Wang; Terri Wrin; Chris Petropoulos; Marc Gurwith; Faruk Sinangil; Patricia D'Souza; Isaac R Rodriguez-Chavez; Allan DeCamp; Mike Giganti; Phillip W Berman; Steve G Self; David C Montefiori Journal: J Infect Dis Date: 2010-08-15 Impact factor: 5.226
Authors: Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Joseph Chiu; Robert Paris; Nakorn Premsri; Chawetsan Namwat; Mark de Souza; Elizabeth Adams; Michael Benenson; Sanjay Gurunathan; Jim Tartaglia; John G McNeil; Donald P Francis; Donald Stablein; Deborah L Birx; Supamit Chunsuttiwat; Chirasak Khamboonruang; Prasert Thongcharoen; Merlin L Robb; Nelson L Michael; Prayura Kunasol; Jerome H Kim Journal: N Engl J Med Date: 2009-10-20 Impact factor: 91.245
Authors: Lawrence Corey; Peter B Gilbert; Georgia D Tomaras; Barton F Haynes; Giuseppe Pantaleo; Anthony S Fauci Journal: Sci Transl Med Date: 2015-10-21 Impact factor: 17.956
Authors: Chitraporn Karnasuta; Siriwat Akapirat; Sirinan Madnote; Hathairat Savadsuk; Jiraporn Puangkaew; Surawach Rittiroongrad; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Punnee Pitisuttithum; Jaranit Kaewkungwal; James Tartaglia; Faruk Sinangil; Donald P Francis; Merlin L Robb; Mark S de Souza; Nelson L Michael; Jean-Louis Excler; Jerome H Kim; Robert J O'Connell; Nicos Karasavvas Journal: AIDS Res Hum Retroviruses Date: 2017-01-30 Impact factor: 2.205
Authors: Leonie M Weskamm; Anahita Fathi; Matthijs P Raadsen; Anna Z Mykytyn; Till Koch; Michael Spohn; Monika Friedrich; Bart L Haagmans; Stephan Becker; Gerd Sutter; Christine Dahlke; Marylyn M Addo Journal: Cell Rep Med Date: 2022-07-19
Authors: Isabelle M Castro; Michael J Ricciardi; Lucas Gonzalez-Nieto; Eva G Rakasz; Jeffrey D Lifson; Ronald C Desrosiers; David I Watkins; Mauricio A Martins Journal: J Virol Date: 2021-06-24 Impact factor: 5.103
Authors: Erandi Velarde de la Cruz; Lingyun Wang; Deepanwita Bose; Sailaja Gangadhara; Robert L Wilson; Rama R Amara; Pamela A Kozlowski; Anna Aldovini Journal: Front Immunol Date: 2021-06-21 Impact factor: 7.561